The company plans to use the funds for team expansion in India, geographical footprint in other South Asian countries, and invest in clinical trials for their novel in-licensed assets
Sayre Therapeutics will be able to distribute, market and sell LUTRATE Depot in one and three month formulations for India, Sri Lanka, Bangladesh and Nepal